Peter Horby @peterhorby.bsky.social
@PeterHorby
Followers
13K
Following
723
Media
110
Statuses
2K
Moh Family Foundation Professor of Emerging Infections and Global Health. Director, Pandemic Sciences Institute, University of Oxford, UK.
Joined February 2014
Fantastic morning discussing pandemic prevention, One Health and system-wide approaches. Now debating the Pandemic Agreement and what it means in practice.
linkedin.com
A warm welcome to the International Pandemic Sciences Conference 2025 to all our delegates 🌍 Over 500 guests from more than 50 countries are joining us in sunny Oxford and online for two days of...
0
0
2
RT @NDMOxford: In a collaborative new study, researchers at @PSIOxford have partnered with global colleagues to discover how #AI could acce….
0
3
0
RT @remap_cap: REMAP-CAP's @DerdeLennie adds her voice to a beautiful celebration of #InternationalDayofWomenandGirlsinScience 👇.
0
1
0
RT @ALERRT_Global: New publication in The Lancet: Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu.….
0
1
0
There seem to be THREE simultaneous filovirus outbreaks - Marburg in Tanzania, Ebola in DRC (most likely culprit Zaire Ebolavirus) and Sudan Ebolavirus in Uganda. We need adequately funded public health and research and development programmes and support.
Permanent Secretary, Dr. @DianaAtwine addresses the media this afternoon. “An outbreak of Sudan Ebola Virus Disease has been confirmed in Kampala, Uganda following confirmation from 3 National Reference Laboratories.”
2
5
5
Although sotrovimab likely to have no useful activity against current SARS-CoV-2 variants, these data, along with the RECOVERY casirivimab-imdevimab.result, show that mAbs which effectively neutralise can benefit some hospitalised patients.
2
1
5
🔥 RECOVERY sotrovimab result now available. Despite widespread vaccination and natural immunity, sotrovimab reduced mortality in COVID-19 inpatients with high levels of SARS-CoV-2 antigen.
medrxiv.org
Background Sotrovimab is a neutralising monoclonal antibody that has been proposed as a treatment for patients admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label...
1
2
8
RT @WHOAFRO: As #Tanzania responds to the confirmed outbreak of #Marburg virus disease, @WHO is working closely with the national health au….
afro.who.int
Dodoma – Tanzania today confirmed an outbreak of Marburg virus disease in the northwestern Kagera region after one case tested positive for the virus following investigations and laboratory analysis...
0
20
0
Marburg raises its head again: so soon after Rwanda outbreak. There are no approved treatments or vaccines for Marburg - from each outbreak we need to incrementally gather the data we need for effective control and treatment.
WHO informed its Member States and International Health Regulation State Parties of an outbreak of suspected Marburg Virus Disease in the Kagera region of #Tanzania . So far, we are aware of 9 suspected cases incl. 8 deaths across 2 districts. WHO risk assessment of this
0
1
4
Controversial COVID study that promoted unproven treatment retracted after four-year saga . Ironic that the co-authors complain they were “victims of cyber-harassment” - they should try being on the receiving end of HCQ believers, including Raoult himself.
nature.com
Nature - Paper on hydroxychloroquine led by French researcher Didier Raoult is second-most-cited study ever to be withdrawn.
13
14
33
An extraordinarily strong lesson on the importance of good science, critical thinking, and being truly objective. The damage done to trust and to patients by the hydroxycholoroquine debacle should never be repeated. Would love to know the reasons for retraction.
Extraordinary: Raoult’s damaging paper on hydroxychloroquine for COVID-19 finally retracted. So grateful to all the people who helped with the RECOVERY trial, allowing us to debunk the myth of hydroxychloroquine for severe COVID-19.
2
11
31
RT @MartinLandray: Extraordinary: Raoult’s damaging paper on hydroxychloroquine for COVID-19 finally retracted. So grateful to all the pe….
0
82
0
Md Zakiul Hassan recognised as 2024 ISID Emerging Leader
ndm.ox.ac.uk
PSI researcher Md Zakiul Hassan, the inaugural Oxford-MoH Foundation DPhil Scholar, has been recognised as 2024 ISID Emerging Leader in International Infectious Diseases. The award from the Interna...
0
3
3
Influenza going up in the UK. For those involved in the RECOVERY trial of influenza treatments - please try to enrol patients. If this season is short and sharp, we will have a limited time window for recruitment.
0
7
14
Embedding treatment in stronger care systems.
0
1
1
Lancet Infectious Diseases commissioned a series of papers to mark 10 years from the Ebola west Africa outbreak. 2 links below for free access, active until Feb 01, 2025. Ebola disease: bridging scientific discoveries and clinical application:
1
13
22
"A new requirement" that further raises the onerrous burdens of applying for research funding and, ironically, likely increasing the inequality in who is funded to do research (will further concentrate funding in well resourced entities).
Today we've launched a new requirement that all applicants must demonstrate how their research will address existing inequalities in health and social care as a condition of funding. Applicants will now be required to show how inclusion is being built into all stages of the
1
0
5
RT @JakubHantabal: Today I had the pleasure of presenting my DPhil project on host-pathogen interactions of henipaviruses at the @PSIOxford….
0
3
0
RT @EleonoraSberg: I'm a PhD student at @UniofOxford and I think I'm living in a fairytale :-). Foxes playing around in the snow at Magdale….
0
11K
0